CD28 and neoplasm: In this regard, simultaneous multiple interaction T cell engagers (SMITEs) were designed that are composed of two independent BiTEs to enable concurrent recognition of two different TAAs on the tumor cell and of CD3 and CD28 on the effector T cells [40].